Quoin Pharmaceuticals Initiates New Public Offering
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company at the forefront of treating rare and orphan diseases, has embarked on a significant public offering. The offering consists of 15,111,110 ordinary shares, which are represented by American Depositary Shares (ADSs), alongside Series F and G warrants. With shares priced at $0.45 per ADS, the company aims to raise approximately $6.8 million in gross proceeds before deducting fees and expenses.
Details of the Offering
This public offering highlights Quoin's commitment to addressing the unmet medical needs of rare disease patients. The proceeds will be allocated towards various corporate purposes, such as operational expenses and the advancement of Quoin's innovative pipeline. The finalization of this public offering is contingent upon standard closing conditions, with an anticipated closing date set for late December.
Warrants and Existing Agreements
In conjunction with the public offering, the Company has also made adjustments to certain existing warrants held by investors. By renegotiating the terms, Quoin lowers the exercise price of prior warrants from $1.60 to $0.45 per ADS and extends their expiration to December 23, 2029. These changes reflect Quoin's efforts to enhance shareholder value and make investing more appealing.
Future Directions for Quoin Pharmaceuticals
The net funds generated from this offering will enable Quoin Pharmaceuticals to pursue more rigorous research and clinical trials for its product candidates. The focus is on developing innovative therapies for a variety of rare conditions, such as Netherton Syndrome and Epidermolysis Bullosa. These efforts underline Quoin's mission to create meaningful improvements in the quality of life for patients afflicted with challenging health issues.
Company Overview
Quoin Pharmaceuticals Ltd. stands out in the pharmaceutical industry for its dedication to rare and orphan diseases. By advancing therapeutic products, Quoin is determined to innovate treatment possibilities where there are significant gaps in care. The current product pipeline at Quoin features several promising candidates that target a range of rare indications.
Research and Development Focus
Quoin's clinical development strategy is designed to generate substantial data necessary to support regulatory submissions. The company aims to establish a strong clinical foundation that supports effective treatments and sound clinical practices. Achieving success in these clinical studies is essential for Quoin's long-term growth and sustainability.
Investor Relations and Support
Maxim Group LLC is the sole placement agent for this public offering, ensuring a structured approach to managing this substantial financial endeavor. Investors interested in learning more about Quoin's offerings can reach out to the investor relations team for updates and detailed information regarding future developments.
For any inquiries, potential investors can contact:
Investor Relations Contact:
Investor Relations
PCG Advisory
Jeff Ramson
646-863-6893
jramson@pcgadvisory.com
Frequently Asked Questions
What is the purpose of Quoin Pharmaceuticals' public offering?
The public offering aims to raise funds for general corporate purposes, research and development, and operational expenses.
How much is the public offering expected to raise?
The offering is anticipated to raise approximately $6.8 million before fees and expenses.
What changes were made to existing warrants?
Quoin lowered the exercise price of prior warrants from $1.60 to $0.45 and extended their expiration date to December 23, 2029.
What conditions must be met for the offering to close?
The closing of the offering is subject to standard closing conditions which are customary for similar transactions.
Where can I find more information about Quoin Pharmaceuticals?
For further details about the company and its pipeline, interested individuals can visit the Quoin Pharmaceuticals website or contact their investor relations team.
